Abstract
Non-alcoholic steatohepatitis (NASH) is characterized from its early stages by a profound remodeling of the liver microenvironment, encompassing changes in the composition and activities of multiple cell types and associated gene expression patterns. Hyperpolarized (HP) 13C MRI provides a unique view of the metabolic microenvironment, with potential relevance for early diagnosis of liver disease. Previous studies have detected changes in HP 13C pyruvate to lactate conversion, catalyzed by lactate dehydrogenase (LDH), with experimental liver injury. HP \(\propto \)-ketobutyrate (\(\propto \) KB) is a close molecular analog of pyruvate with modified specificity for LDH isoforms, specifically attenuated activity with their LDHA-expressed subunits that dominate liver parenchyma. Building on recent results with pyruvate, we investigated HP \(\propto \) KB in methionine-choline deficient (MCD) diet as a model of early-stage NASH. Similarity of results between this new agent and pyruvate (~ 50% drop in cytoplasmic reducing capacity), interpreted together with gene expression data from the model, suggests that changes are mediated through broad effects on intermediary metabolism. Plausible mechanisms are depletion of the lactate pool by upregulation of gluconeogenesis (GNG) and pentose phosphate pathway (PPP) flux, and a possible shift toward increased lactate oxidation. These changes may reflect high levels of oxidative stress and/or shifting macrophage populations in NASH.
Similar content being viewed by others
![](https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fsrep46014/MediaObjects/41598_2017_Article_BFsrep46014_Fig1_HTML.jpg)
Introduction
About one third of the global population is believed to have non-alcoholic fatty liver disease (NAFLD)1, or intrahepatic triglyceride content exceeding the normal level required for cellular housekeeping, in the absence of significant alcohol consumption. While also detectable by increased echogenicity on ultrasound, the gold standard method for quantifying liver fat content is MRI proton density fat fraction (MRI-PDFF), in fact providing the widely accepted definition of NAFLD as > 5% MRI-PDFF2. Only a subset of ~ 20% patients with NAFLD progress to non-alcoholic steatohepatitis (NASH)3, the dangerous hepatic inflammatory state that is perhaps the most relevant clinical entity from the standpoint of early diagnosis of liver disease. NASH carries high risks of transition to critical liver disease states of cirrhosis and/or hepatocellular carcinoma (HCC)4, and will soon become the leading cause of liver transplantation5. Emerging therapeutic options including pharmaceutical drugs6 and bariatric surgery7 show significant potential to reverse the course of NASH, if detected early.
Unfortunately, current clinical methods for diagnosis of NASH are extremely limited8. The gold standard method for diagnosing NASH is liver biopsy, which is an expensive surgical procedure that carries non-negligible risks to the patient and is therefore unsuitable for screening or tracking this chronic disease over time. Thus there is a pressing need for simpler tests that could serve as early NASH markers. Emerging imaging-based approaches include ultrasound- or MR-elastography9,10, and collagen-targeted molecular imaging probes11,12. However, these methods primarily target fibrosis, which arises in bulk relatively late in the course of disease. Therapeutic options are more likely to be successful if disease is detected early.
NASH is characterized from earlier disease stages by a profound, dynamic remodeling of the liver microenvironment, including changes in the composition and activities of hepatocyte, stellate, endothelial, and immune cell types13. Central molecular features include changes in the expression of genes associated with oxidative stress, immune response, and fibrosis14. Large scale displacement of the abundant Kupffer cell population by monocyte-derived macrophages (MoMF’s) has also recently been recognized as an essential feature of NASH15, driving its altered bulk transcriptomic profile16. The metabolic programming and resulting functions of these MoMF’s is an area of intense current research17.
Hyperpolarized (HP) 13C MRI is an emerging medical imaging modality for mapping real-time metabolic activity 18, especially the proximal metabolic fates of [1-13C]pyruvate. The technology is readily translatable into human studies19, with an increasing number of research centers having access to the technology. The HP 13C scan can be executed as a ~ 2 min add-on to a conventional MRI imaging exam, and does not involve any ionizing radiation. Diffuse liver disease appears to be an especially suitable disease target, as current molecular imaging tools play only a limited current role in this context, with many existing PET tracers displaying non-specific label accumulation in liver. Several preclinical studies have reported large changes in the apparent metabolic conversion of HP [1-13C]pyruvate to [1-13C]lactate, catalyzed by lactate dehydrogenase (LDH), with liver injury20,21. A recent study found that hepatic pyruvate to lactate conversion was decreased in NAFLD/NASH, starting at early disease stages22, contrasting with other studies showing lactate elevation in hepatotoxic models20,21, an alternate dietary model of NAFLD23, and diabetes24. Although monocarboxylate transporter (MCT) expression is believed to be a major factor in the context of HP tumor imaging25,26, it is not clear whether this generalizes to non-malignant tissues. Furthermore, the extent to which hepatic HP signals reflect the metabolic activities of different liver cell types, which are fundamentally reorganized in NASH, is currently unclear. Thus, molecular signatures of early-stage NASH that may be accessible via HP 13C MRI require further clarification.
HP [1-13C]\(\propto \)-ketobutyrate (\(\propto \) KB) is a close molecular analog of [1-13C]pyruvate that exhibits isoform-level selectivity for LDH27,28, but otherwise shares many characteristics with pyruvate including high polarization, long T1 relaxation time, rapid metabolic rate, and low toxicity. As compared with pyruvate, \(\propto \) KB has sharply attenuated activity with “muscle-type” (M) subunits of LDH encoded by LDHA, which are well known to be the dominant form of LDH expressed by liver parenchyma29. In comparison, reactivity of \(\propto \) KB with “heart-type” (H) subunits of LDH encoded by LDHB remains intact. The differential expression pattern of LDHA vs LDHB throughout the body is commonly rationalized in terms of the differing kinetic characteristics of H-type subunits of LDH (LDHB-expressed), which favor oxidation of lactate, as compared to M-type subunits (LDHA-expressed), which favor lactate production. In this study, we show how the “LDHB-weighting” inherent to HP \(\propto \) KB MRI, interpreted together with gene expression data, can inform our understanding of the results of HP liver MRI in the context of early NASH diagnosis.
Results
Hyperpolarized 13C MRI shows diminished cytoplasmic reducing capacity in early-stage NASH
Representative HP 13C metabolite images with corresponding liver-localized spectra and summary data are shown in Fig. 1. The HP \(\propto \) HB/\(\propto \) KB area under the curve (AUC) ratio in liver was 0.25 \(\pm \) 0.05 (mean \(\pm \) s.d.) at baseline and 0.13 \(\pm \) 0.03 after six weeks MCD diet, meaning that the apparent metabolic conversion of \(\propto \) KB to \(\propto \) HB was 52% lower in rats with experimental liver injury (p = 0.003, unpaired two-tailed t-test) as compared with baseline. The magnitude of the observed decrement in cytoplasmic reducing capacity is very similar to the prior result with the closely related probe HP [1-13C]pyruvate22, which reported an analogous decrease in pyruvate-to-lactate conversion of 45% at the same six week time point.
HP [1-13C]\(\propto \) KB MRI in rodent model of early-stage NASH. (A) Summary results showing a mean drop of 52% in the apparent metabolic conversion of \(\propto \) KB to \(\propto \) HB in liver after six weeks MCD diet (p = 0.003). (B) Example coronal HP 13C metabolite images through rat abdomen, shown as color overlays on 1H images in grayscale for anatomic reference. Reference 1H images without overlay are shown in leftmost column. Vial containing enriched urea sample for 13C signal reference is also seen in these images. Hepatic 13C MR spectra from locations indicated by black lines are shown in the rightmost column. The peak at ~ 180 ppm corresponds to a hydrate of \(\propto \) KB, not a metabolite.
MCD diet induces early-stage NASH in rats within six week
Consistent with numerous prior studies22,30,31, MCD diet was effective at inducing severe NAFLD in rats within a short period of time. As depicted in Fig. 2A, MRI-PDFF showed a large increase in triglyceride 1H MRI signals in rat liver from 0.33 \(\pm \) 0.57 to 20.0 \(\pm \) 3.6% (p = 0.001) at six weeks. The appearance of hepatic steatosis was accompanied by a mean weight loss of 15 \(\pm \) 0.7% over the six weeks (p = 0.003), a known effect of the MCD model. As depicted in Fig. 2B, venous plasma sampling revealed elevation of liver enzymes consistent with liver injury. Specifically, ALT increased from 24 \(\pm \) 16 to 60 \(\pm \) 6.5 IU/L (p = 0.02), and AST trended upward from 52 \(\pm \) 4.2 to 63 \(\pm \) 8.1 IU/L (p = 0.12). Histology also revealed clear evidence of fatty liver disease (Fig. 3). Most evident was extensive macrovesicular steatosis at six weeks on diet, seen as the white droplets in Figs. 3C, D. Modest scarring was also detectable, as were sparse inflammatory foci. Computerized pathology readings, summarized in Fig. 3E, indicated early NASH. NAS scores were significantly elevated from 0.60 \(\pm \) 0.55 at 0 weeks to 4.0 \(\pm \) 0.8 at 6 weeks (p = 0.0001). Note that the accepted cutoff for human NASH is a NAS score of 532.
Conventional non-invasive clinical markers of NAFLD/NASH in rodent model of early-stage NASH. (A) Example 1H MRI-PDFF images and group data showing elevation of hepatic fat signal fraction in rats fed MCD diet (0.33 \(\pm \) 0.57 to 20.0 \(\pm \) 3.6%, p = 0.001). (B) Results of hepatic function panel showing elevated liver enzymes in rats fed MCD diet (ALT: 24 \(\pm \) 16 to 60 \(\pm \) 6.5 IU/L, p = 0.02; AST: 52 \(\pm \) 4.2 to 63 \(\pm \) 8.1 IU/L, p = 0.12).
Histopathology of NAFLD/NASH in rodent model of early-stage NASH. (A) Example stained liver tissue sections demonstrating histologic features of NAFLD/NASH in livers harvested from MCD model. H&E (A, C) and Sirius red (B, D) stained sections are shown. Specific observations are extensive macrovesicular steatosis, sparse inflammatory foci, and moderate excess collagen deposition (Sirius red). (E) Automated discrete scoring of Trichrome slides demonstrates elevated NAS scores in rodents fed MCD diet, as well as increased fibrosis (NAS: 0.60 \(\pm \) 0.55 to 4.0 \(\pm \) 0.8, p = 0.0001). Error bars show s.d.’s of the sample means.
Early NASH transcriptome reveals potential mechanisms of diminished cytoplasmic reducing capacity
Bulk RNAseq detected significantly different expression of 6949/10,947 genes in rats with early-stage NASH. We first checked hallmark genes associated with oxidative stress and fibrosis, to confirm expected changes associated with liver injury (Fig. 4A). We next examined differential expression of individual genes proximal to pyruvate metabolism (Fig. 4B), to look for factors that could potentially provide a direct explanation for the HP results. Expression of MCT1&4 was not significantly different between groups. Notably, LDHB was upregulated while LDHA was downregulated, which could indicate a shift toward increased lactate oxidation in early-stage NASH. Of largest quantitative significance among these genes, the key cataplerotic enzyme PEPCK (rate-limiting step of gluconeogenesis or GNG) was upregulated 3.9-fold, which would tend to deplete TCA intermediates and consequently also the lactate pool, potentially decreasing the apparent metabolic conversion of \(\propto \) KB and pyruvate by depleting the pool of lactate available for isotopic exchange flux33,34. We also detected a modest upregulation of G6PD (rate-limiting step of pentose phosphate pathway or PPP) that could also tend to draw carbon away the lactate-pyruvate pool.
Changes in liver gene expression in rodent model of early-stage NASH. (A) Upregulation of selected genes associated with inflammation (transforming growth factor or TGF-\(\beta \)), oxidative stress (catalase), and fibrosis (alpha-1 type-1 collagen or Col1A) in MCD model. (B) Changes in gene expression proximal to pyruvate metabolism with relevance to HP MRI results. (C) Heat maps for two highly enriched gene sets, related to oxidative stress-induced apoptosis (left) and macrophage migration (right).
Gene set analysis contextualizes these results with lower dependence on changes in any particular gene or metabolic segment. Of 2222 total gene sets analyzed, among the top seven most highly enriched GOBP gene sets in rats with early-stage NASH were “Negative regulation of oxidative stress induced intrinsic apoptotic signaling pathway” (NES = 2.06, p < 0.001, FDR q-val = 0.067) and “Macrophage migration (NES = 2.00, p < 0.001, FDR q-val = 0.10). These enrichments (Fig. 4C) highlight the established role of excess ROS production35,36, as well as recent findings about shifting inflammatory cell populations in NASH pathogenesis15.
Discussion
This study showed that HP 13C \(\propto \) KB can be used to detect hepatic metabolic changes in early NASH. LDHB-weighted reduction of \(\propto \) KB to \(\propto \) HB was attenuated to a very similar extent as the reduction of pyruvate to lactate in a recent study that employed the same model of early NASH22, despite changes in the relative expression levels of LDHA and LDHB. This suggests a limited direct role for LDH expression in HP contrast in the present context. More likely, the apparent fluxes of either probe along the accessible proximal segments are influenced by wider effects on intermediary metabolism.
Evidence from our gene expression data suggests that increased GNG and PPP flux in early NASH could each deplete the lactate pool in a manner that could lead to the observed result, by limiting isotopic exchange flux33,34. Increased expression of LDHB relative to LDHA in early NASH could also contribute to such an effect by favoring lactate oxidation. Of course, gene expression is not to be equated with metabolic fluxes, or even protein levels. Besides protein levels, metabolic fluxes can also depend on substrate concentrations, allosteric interactions, enzyme compartmentalization, and posttranslational modification (phosphorylation), among other factors. Nevertheless, many enzymes are known to be regulated at the level of transcription, including PEPCK37 and, to a lesser extent, G6PD38. Thus, the changes in mRNA levels of these two enzymes probably do actually result in increased GNG and PPP flux. These pathways may be less important in the other models of liver injury that reported lactate elevation20,21,23,24.
The observed upregulation of GNG and PPP pathways is likely related to high levels of oxidative stress, which is a key pathway of liver injury in NASH through oxidative stress-induced apoptosis39. Elevated mitochondrial anaplerotic/cataplerotic activity is coordinated energetically with oxidative metabolism, coupling elevated GNG to higher levels of oxidative stress40,41. Moreover, GNG can be induced directly by oxidative stress42. The PPP generates NADPH in part to combat oxidative stress, and is thought to be activated directly in response to oxidative stress via the NADPH/NADP+ ratio38. PPP flux can also be induced by acute application of oxidative stress43. Obese Zucker rats have been shown to have higher hepatic PPP flux than lean controls at 8 weeks, but not at 16 weeks, highlighting the importance of this pathway in early disease44. A previous study applied the HP 13C probe [1-13C]dehydroascorbate to directly probe hepatic oxidative stress in the MCD diet45. Interestingly, an analogous drop in the reduction of DHA to vitamin C was observed in rodents with NAFLD/NASH in that study, in a reaction where the alternate co-factor NADPH is the electron donor.
It is important to evaluate our results in the context of multiple quantitatively important cell types present in liver. Hepatocytes constitute the largest liver cell fraction, but Kupffer cells are the next largest and account for ~ 15% of all liver cells, representing the single largest resident macrophage population in the body46. Considering the high metabolic capacity of macrophages and their high cell fraction in liver, macrophages could account for some part of the metabolic changes detected by HP imaging. In contrast with hepatocytes, macrophages (both resident Kupffer cells and MoMF’s) are known for highly plastic expression programs shaped by their local microenvironment47, and can express LDHA and/or LDHB48. The classical M2 polarization state of macrophages favors lactate oxidation and is regarded to be anti-inflammatory49, and could be reflected in the opposite changes in expression of LDHA&B detected in early NASH in this study. Thus, replacement of the resident Kupffer cell population with MoMF’s15 may also have contributed to the detected metabolic shift.
Six weeks on MCD diet was confirmed as an appropriate time point for modeling early NASH in rats through blood testing and automated pathology readings50, in agreement with prior results with the same model22. Automated detection of inflammation was less reliable than any of the other scored pathology criteria, likely stemming from the inherent difficulty of detecting inflammatory foci and distinguishing these cells from erythrocytes, together with the limited available training data and potential deviations from our data such as differences in the details of staining techniques between labs.
Although it effectively mimics several aspects of human NASH over a short period of time, the MCD diet has some important limitations. The biggest limitations of the MCD model are the significant weight loss exhibited during disease induction and the absence of insulin resistance, both us which are inconsistent with the typical picture of human NASH, which has tight associations with obesity and type 2 diabetes51. Human NASH, representing sustained liver damage over long periods of time, is known to be more severe histopathologically than existing NASH models. It is difficult if not impossible to cause cirrhosis in rodents without repeated toxic insults. Only male rats, which are known to develop greater liver injury on the MCD diet in comparison with females52, were included in this study.
HP 13C data should be interpreted as only one part of the overall MRI scan session, of which the HP 13C scan is an add-on component. The 1H-based MRI-PDFF scans in this study showed large signal changes on MCD diet, much larger fractionally than the HP 13C changes, with the prior study by Piraquive et al.22 showing that MRI-PDFF changes more rapidly than HP 13C metabolite ratios. However, depiction of the presence and amount of liver fat has limited value for detection of NASH, with liver biopsy remaining the gold standard. Arguably, the biggest potential added value for molecular imaging methods such as HP 13C in this context would be in differentiating benign fatty liver from fatty liver with inflammation (i.e., NASH). This could be assessed for the \(\alpha \) KB probe by adding more study time points with matching pathology readings.
In summary, HP 13C MRI provides metabolic readouts of early-stage NASH in rodent models, although underlying contrast mechanisms and relevance to human disease have yet to be fully established.
Methods
Animal model
A total of 14 adult male Sprague Dawley rats (Charles River) were studied, starting at 12 weeks of age. A sub-group of these rats were imaged at baseline (n = 4) and after six weeks on a custom diet deficient in methionine and choline (n = 5) (MCD diet, Envigo TD.90262), a frequently utilized model of NAFLD/NASH30,31. Fixed and frozen liver tissue samples were harvested at both time points in sub-groups of rats (fixed—n = 5 at baseline, n = 4 at 6 weeks; frozen—n = 3 at baseline, n = 3 at 6 weeks). Venous plasma samples were also collected in sub-groups at both time points (n = 3 at baseline, n = 3 at 6 weeks). All experimental protocols were approved by the Institutional Animal Care and Use Committee (IACUC) at Washington University (protocol #22-0054), and all methods were carried out in accordance with relevant guidelines and regulations. All methods are reported in accordance with the ARRIVE guidelines.
13C/1H MRI
MRI scanning was conducted in a compact, cryogen-free PET/MR system (MR Solutions, Guildford, UK) equipped with a dual-tuned 13C/1H radiofrequency coil designed for imaging rats. This system has a variable magnetic field strength of 7 T/3 T, and was ramped to 3 T for the present study. For each imaging study, 130 \(\mu \)L [1-13C]\(\propto \) KB acid mixed with 15 mM trityl radical OX063 was hyperpolarized using a GE 5 T SPINlab (GE Healthcare). At the time of the HP experiment, each HP sample was dissolved with 18 mL superheated water and neutralized using NaOH/Tris buffer. 2.4 mL contrast agent was injected into the rat tail vein over 10 s. HP 13C images through rat abdomen were acquired using a previously described flyback echo planar spectroscopic imaging (EPSI) pulse sequence 53, with spatial resolution of 5 mm × 5 mm × 20 mm and temporal resolution of 4 s. Multi-band spectral-spatial RF excitation was used to apply a smaller flip angle of 5 \(^\circ \) on the primary substrate [1-13C]\(\propto \) KB and 12\(^\circ \) on [1-13C]\(\propto \) HB, conserving the magnetization of the primary substrate for subsequent metabolic conversion54. Metabolite data was quantified by regional integration and summation over time to produce metabolite AUC ratios. To quantify hepatic triglyceride content, multi-echo 1H GRE images were acquired with six echoes with TE1 = 2.21 ms and \(\Delta \)TE = 1.68 ms. Resulting data were fit using the LIPOQUANT (Liver Imaging of Phase interference related signal Oscillation and QUANTification) package in MATLAB to compute MRI-PDFF. T1-weighted MRI images were also collected for anatomic reference.
Blood testing
To measure conventional markers of liver injury, venous blood plasma samples were collected for a hepatic function panel conducted by a CLIA certified laboratory. The panel measured albumin, alkaline phosphatase, alanine transaminase (ALT), aspartate aminotransferase (AST), direct and total bilirubin, and total protein.
Pathology
Formalin fixed, paraffin embedded liver tissue sections were stained with H&E, Sirius red, and Mason’s trichrome, and whole slides were digitized at 20 × magnification. Digital trichrome data were analyzed using a “pathologist-like” deep learning (DL) system that outputs discrete NAFLD-related histological feature scoring based on hepatocyte ballooning (0–2), inflammation (0–2), steatosis (0–3), and fibrosis (0–4)32,50. The code analyzes trichrome tiles (299 × 299 px2, resampled to 0.44 \(\mu \)m/px) with convolutional neural networks (CNN’s) trained using gold standard scoring of thousands of tiles by an expert pathologist. All feature detection models were used without modification, except for an adjustment to the inflammation score cutoffs. The NAFLD Activity Score (NAS) was computed as the sum of scores for ballooning, inflammation, and steatosis, in the usual manner utilized by the NASH Clinical Research Network (CRN)32.
RNAseq
> 30 \(\mu \)g RNA was isolated from each frozen liver tissue sample. The bulk RNAseq procedure included library preparation based on poly(A) enrichment, ~ 30 M 2 × 150 reads from the NovaSeq S4 system. Gene set enrichment analysis was performed on the resulting mRNA expression data using GSEA (version 4.3.2), with the C5 gene ontology (GO) biological processes (BP) gene set (v2023). Rat genes were mapped to human orthologs based on MSigDB (v2023).
Data availability
The datasets generating during and/or analyzed during the current study are available from the corresponding author on reasonable request.
References
Riazi, K. et al. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 7(9), 851–861 (2022).
Reeder, S. B., Cruite, I., Hamilton, G. & Sirlin, C. B. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J. Magn. Reson. Imaging 34(4), 729–749 (2011).
Estes, C. et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J. Hepatol. 69(4), 896–904 (2018).
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O. & Heikenwalder, M. From NASH to HCC: Current concepts and future challenges. Nat. Rev. Gastroenterol. Hepatol. 16(7), 411–428 (2019).
Younossi, Z. M. et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 64(5), 1577–1586 (2016).
Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M. & Alkhouri, N. Challenges and opportunities in NASH drug development. Nat. Med. 29(3), 562–573 (2023).
Aminian, A. et al. Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA 326(20), 2031–2042 (2021).
Sumida, Y., Nakajima, A. & Itoh, Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J. Gastroenterol. 20(2), 475–485 (2014).
Bonder, A. & Afdhal, N. Utilization of fibroscan in clinical practice. Curr. Gastroenterol. Rep. 16(2), 372 (2014).
Idilman, I. S., Li, J., Yin, M. & Venkatesh, S. K. MR elastography of liver: Current status and future perspectives. Abdom. Radiol. 45(11), 3444–3462 (2020).
Izquierdo-Garcia, D. et al. Biodistribution, dosimetry, and pharmacokinetics of (68)Ga-CBP8: A type I collagen-targeted PET probe. J. Nucl. Med. 64(5), 775–781 (2023).
Zhou, I. Y., Tanabe, K. K., Fuchs, B. C. & Caravan, P. Collagen-targeted molecular imaging in diffuse liver diseases. Abdom. Radiol. 45(11), 3545–3556 (2020).
Rui, L. & Lin, J. D. Reprogramming of hepatic metabolism and microenvironment in nonalcoholic steatohepatitis. Annu. Rev. Nutr. 42, 91–113 (2022).
Subudhi, S. et al. Distinct hepatic gene-expression patterns of NAFLD in patients with obesity. Hepatol. Commun. 6(1), 77–89 (2022).
Daemen, S. et al. Dynamic shifts in the composition of resident and recruited macrophages influence tissue remodeling in NASH. Cell Rep. 34(2), 108626 (2021).
Hendrikx, T. et al. Soluble TREM2 levels reflect the recruitment and expansion of TREM2(+) macrophages that localize to fibrotic areas and limit NASH. J. Hepatol. 77(5), 1373–1385 (2022).
Vonderlin, J., Chavakis, T., Sieweke, M. & Tacke, F. The multifaceted roles of macrophages in NAFLD pathogenesis. Cell Mol. Gastroenterol. Hepatol. 15(6), 1311–1324 (2023).
Golman, K., In ’t Zandt, R. & Thaning, M. Real-time metabolic imaging. Proc. Natl. Acad. Sci. USA 103(30), 11270–11275 (2006).
Wang, Z. J. et al. Hyperpolarized (13)C MRI: State of the art and future directions. Radiology 291(2), 273–284 (2019).
Josan, S. et al. Assessing inflammatory liver injury in an acute CCl4 model using dynamic 3D metabolic imaging of hyperpolarized [1-(13)C]pyruvate. NMR Biomed. 28(12), 1671–1677 (2015).
Kim, G. W. et al. Noninvasive biomarkers for acute hepatotoxicity induced by 1,3-dichloro-2-propanol: Hyperpolarized 13C dynamic MR spectroscopy. Magn. Reson. Imaging 34(2), 159–165 (2016).
Piraquive, J. et al. Hyperpolarized [1–13C]pyruvate MRSI to detect metabolic changes in a methionine and choline-deficient diet rat model of fatty liver disease. Magnet. Reson. Med. 91, 1625–1636 (2023).
Moon, C. M. et al. Metabolic biomarkers for non-alcoholic fatty liver disease induced by high-fat diet: In vivo magnetic resonance spectroscopy of hyperpolarized [1-(13)C] pyruvate. Biochem. Biophys. Res. Commun. 482(1), 112–119 (2017).
von Morze, C. et al. Non-invasive detection of divergent metabolic signals in insulin deficiency vs insulin resistance in vivo. Sci. Rep. 8(1), 2088 (2018).
Granlund, K. L. et al. Hyperpolarized MRI of human prostate cancer reveals increased lactate with tumor grade driven by monocarboxylate transporter 1. Cell Metab. 31(1), 105-114.e3 (2020).
Rao, Y. et al. Hyperpolarized [1-(13)C]pyruvate-to-[1-(13)C]lactate conversion is rate-limited by monocarboxylate transporter-1 in the plasma membrane. Proc. Natl. Acad. Sci. USA 117(36), 22378–22389 (2020).
Kim, M. J. & Whitesides, G. M. L-Lactate dehydrogenase: Substrate specificity and use as a catalyst in the synthesis of homochiral 2-hydroxy acids. J. Am. Chem. Soc. 110(9), 2959–2964 (1988).
von Morze, C. et al. Hyperpolarized [(13)C] ketobutyrate, a molecular analog of pyruvate with modified specificity for LDH isoforms. Magn. Reson. Med. 75(5), 1894–1900 (2016).
Markert, C. L. & Ursprung, H. The ontogeny of isozyme patterns of lactate dehydrogenase in the mouse. Dev. Biol. 5, 363–381 (1962).
Macfarlane, D. P. et al. Metabolic pathways promoting intrahepatic fatty acid accumulation in methionine and choline deficiency: Implications for the pathogenesis of steatohepatitis. Am. J. Physiol. Endocrinol. Metab. 300(2), E402-409 (2011).
Mu, Y. P., Ogawa, T. & Kawada, N. Reversibility of fibrosis, inflammation, and endoplasmic reticulum stress in the liver of rats fed a methionine-choline-deficient diet. Lab. Invest. 90(2), 245–256 (2010).
Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41(6), 1313–1321 (2005).
Day, S. E. et al. Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nat. Med. 13(11), 1382–1387 (2007).
Hurd, R. E. et al. Exchange-linked dissolution agents in dissolution-DNP (13)C metabolic imaging. Magn. Reson. Med. 70(4), 936–942 (2013).
Alkhouri, N., Carter-Kent, C. & Feldstein, A. E. Apoptosis in nonalcoholic fatty liver disease: Diagnostic and therapeutic implications. Expert Rev. Gastroenterol. Hepatol. 5(2), 201–212 (2011).
Masarone, M. et al. Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease. Oxid. Med. Cell Longev. 2018, 9547613 (2018).
Yang, J., Reshef, L., Cassuto, H., Aleman, G. & Hanson, R. W. Aspects of the control of phosphoenolpyruvate carboxykinase gene transcription. J. Biol. Chem. 284(40), 27031–27035 (2009).
Stanton, R. C. Glucose-6-phosphate dehydrogenase, NADPH, and cell survival. IUBMB Life 64(5), 362–369 (2012).
Kanda, T. et al. Apoptosis and non-alcoholic fatty liver diseases. World J. Gastroenterol. 24(25), 2661–2672 (2018).
Satapati, S. et al. Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver. J. Clin. Invest. 125(12), 4447–4462 (2015).
Sunny, N. E., Parks, E. J., Browning, J. D. & Burgess, S. C. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab. 14(6), 804–810 (2011).
Ito, Y., Oumi, S., Nagasawa, T. & Nishizawa, N. Oxidative stress induces phosphoenolpyruvate carboxykinase expression in H4IIE cells. Biosci. Biotechnol. Biochem. 70(9), 2191–2198 (2006).
Janero, D. R., Hreniuk, D. & Sharif, H. M. Hydroperoxide-induced oxidative stress impairs heart muscle cell carbohydrate metabolism. Am. J. Physiol. 266, C179-188 (1994).
Jin, E. S., Lee, M. H., Murphy, R. E. & Malloy, C. R. Pentose phosphate pathway activity parallels lipogenesis but not antioxidant processes in rat liver. Am. J. Physiol. Endocrinol. Metab. 314(6), E543–E551 (2018).
Wilson, D. M. et al. Hyperpolarized (13)C spectroscopic evaluation of oxidative stress in a rodent model of steatohepatitis. Sci. Rep. 7, 46014 (2017).
Sitia, G. et al. Kupffer cells hasten resolution of liver immunopathology in mouse models of viral hepatitis. PLoS Pathog. 7(6), e1002061 (2011).
Krenkel, O. & Tacke, F. Liver macrophages in tissue homeostasis and disease. Nat. Rev. Immunol. 17(5), 306–321 (2017).
Manoharan, I., Prasad, P. D., Thangaraju, M. & Manicassamy, S. Lactate-dependent regulation of immune responses by dendritic cells and macrophages. Front. Immunol. 12, 691134 (2021).
Murray, P. J. Macrophage polarization. Annu. Rev. Physiol. 79, 541–566 (2017).
Heinemann, F., Birk, G. & Stierstorfer, B. Deep learning enables pathologist-like scoring of NASH models. Sci. Rep. 9(1), 18454 (2019).
Younossi, Z. et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 15(1), 11–20 (2018).
Kirsch, R. et al. Rodent nutritional model of non-alcoholic steatohepatitis: Species, strain and sex difference studies. J. Gastroenterol. Hepatol. 18(11), 1272–1282 (2003).
von Morze, C. et al. Multi-band echo-planar spectroscopic imaging of hyperpolarized (13)C probes in a compact preclinical PET/MR scanner. Magn. Reson. Med. 87(5), 2120–2129 (2022).
Larson, P. E. et al. Multiband excitation pulses for hyperpolarized 13C dynamic chemical-shift imaging. J. Magn. Reson. 194(1), 121–127 (2008).
Acknowledgements
We acknowledge funding from NIH S10 OD023580 and R01 DK115987. We gratefully acknowledge the Institute of Clinical and Translational Sciences (ICTS) at Washington University for funding the RNAseq studies. We also acknowledge the assistance of several university core facilities at Washington University: (1) Core Lab for Clinical Studies (CLCS)—blood testing. (2) Anatomic and Molecular Pathology (AMP) Core Labs—slide preparation. (3) Digital Imaging Center-- digitization of slides. (4) Tissue Procurement Core (TPC)—RNA isolation. (5) Genome Technology Access Center (GTAC)—RNAseq.
Author information
Authors and Affiliations
Contributions
C.V.M. and M.A.O. designed the study. C.V.M., T.B., and A.S. performed the experiments. W.M.S. and K.I.S. provided important assistance with the experiments and contributed to the discussion. C.V.M. analyzed the data and prepared the manuscript. C.V.M., T.B., A.S., W.M.S., K.I.S., and M.A.O. reviewed the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
von Morze, C., Blazey, T., Shaw, A. et al. Detection of early-stage NASH using non-invasive hyperpolarized 13C metabolic imaging. Sci Rep 14, 14854 (2024). https://doi.org/10.1038/s41598-024-65951-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-024-65951-z
- Springer Nature Limited